上海仁度生物科技股份有限公司 2025年年度业绩预告

Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 7.20 million and 10.80 million yuan, representing an increase of 15.01 million to 18.61 million yuan compared to the previous year, indicating a turnaround from loss to profit [3][5] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -14.50 million and -11.00 million yuan, which is an improvement of 5.06 million to 8.56 million yuan compared to the previous year [3][5] - The previous year's net profit attributable to shareholders of the parent company was -7.81 million yuan, with a total profit of -15.22 million yuan [5][6] Group 2 - The company has implemented cost reduction and efficiency improvement measures, leading to a year-on-year decrease in period expenses [7] - The company has strengthened accounts receivable management, recovering some receivables from previous years, which allowed for the reversal of some impairment losses [7]